Todas las noticias

Committed to a growth trajectory, Spineway saw its sales accelerate over the 2nd quarter 2022 to total turnover of 1,8 M€, an increase of 74% compared to last year, despite a still fragile and uneven context of recovery in the areas where it operates. This performance brings revenue for the first half 2022 to 3,1M€ (+65% compared to S1 2021). This allows the Group to exceed the turnover of the 1st half 2019 (before the crisis) by 19%, which amounted to 2,6 M€.

This congress was the opportunity to present several new products for the first time and, in particular theranges resulting from the acquisition of the company Distimp (KAPHORN, VEOS, ACIFBOX). This expansion of its implants’ ranges for spine surgery of complex pathologies is part of the group's strategy to become a key player of the market;

In line with the last quarter of 2021, Spineway confirms its growth momentum and totals revenues of €1.3 million for the first quarter of 2022, up 55% compared to the year 2021. The latter benefits from the synergies implemented with Distimp, the growth of sales in France and positive commercial orientation in Latin America.

The Annual and Extraordinary General Meeting of Spineway held on Friday, 23 March 2022 at 4:00 p.m. at at the Group's headquarters was unable to be held due to a lack of quorum for both the resolutions falling within the competence of the ordinary and extraordinary general meeting.

Spineway informs its shareholders that they are convened to a Combined General Meeting on Friday, March 23, 2022 at 4:00 p.m. at the Group's headquarters, 7 allée Moulin Berger in Ecully .(69).

Spineway confirms sound orientation of its 2021 fiscal year with a turnover of €4.3 million1 up 27% compared to 2020, despite the still penalizing pandemic context. This growth is driven by a fourth quarter at €1.3 million (+26%) and is accompanied by an improvement in all the Group's results.

This growth was driven in particular by high sales performances in the Group's historical areas. Thus, Latin America recorded revenues of nearly €2 million, up 33% compared to fiscal year 2020, despite a still complicated situation; while sales in Asia reached €1 million, up 19% compared to 2020.

After a dynamic 2nd quarter, Spineway consolidated its growth in Q3 with revenues of €1.1m, an improvement or 22% as compared to Q3 2020, bringing 9-month activity to 2.9m (+27%). The Group is thus seeing an increase in its sales activity across all of its operating regions, excluding the USA. Moreover, the more favourable sales mix, oriented towards implants and higher value-added product lines, should contribute to improving the Group’s margins.

Spineway confirmed a sharp 153% 2021 half-year turnover increase compared with 2020 same period despite an international economic context still disrupted by the worldwide pandemic. The sales recovery in its main territories allowed the Group to increase its turnover to €1 1885K as at 30 June 2021 and to benefit from a growth of 31% compared with 2020 first semester. The integration of Distimp will enable the group to increase its products order and to develop its sales in the domestic market in the months to come.